As another imperfect approach to estimating the analytical sensitivity, we generated synthetic amyloid products of AD-seeded AD RT-QuIC assays, with known total concentration of the tau molecules, and used them as surrogate seeds in end-point dilution AD RT-QuIC assays. The gene discussed is MAPT; the disease is Alzheimer disease.